Risks and benefits of therapy with flumazenil (Anexate) in mixed drug intoxications
| Autor: | Eran Geller, B. Marchant, Schaller, P. Crome, M. Ectors, G. Scollo-Lavizzari |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Drug
Flumazenil medicine.medical_specialty medicine.drug_class Sedation media_common.quotation_subject Antidepressive Agents Tricyclic Drug overdose Benzodiazepines Risk Factors Intensive care Medicine Humans In patient Drug Interactions Risks and benefits Coma Intensive care medicine media_common Benzodiazepine business.industry medicine.disease Neurology Anesthesia Neurology (clinical) medicine.symptom Drug Overdose business medicine.drug |
| Zdroj: | European neurology. 31(4) |
| ISSN: | 0014-3022 |
| Popis: | Flumazenil, the first specific benzodiazepine (BZD) antagonist, is one of the most innovative drugs to become available within the last few years. Flumazenil is indicated for the reversal of the centrally depressant effects of BZDs, in BZD-induced anaesthesia, in BZD sedation in intensive care and in patients comatose after drug overdoses including BZDs. A conference of experts experienced in the treatment of mixed drug overdoses by various means, including flumazenil, was held in order to try to reach a consensus regarding the safe use of flumazenil in this indication. From the knowledge and experience gained to date, it was concluded that flumazenil may be useful and safe in the treatment of suspected BZD and mixed drug overdoses, provided that the appropriate precautions are observed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|